摘要
目的观察Ⅳ期肺腺癌患者采用紫杉醇脂质体联合卡铂治疗的疗效及远期生存情况。方法选择医院2013年1月-2014年5月收治的Ⅳ期肺腺癌患者50例,给予紫杉醇脂质体联合卡铂治疗,再选择医院同期收治的Ⅳ期肺腺癌患者50例,给予培美曲塞联合卡铂治疗,观察两组患者近期疗效及不良反应发生情况,两组患者均给予20个月随访,观察两组患者远期生存情况。结果经过治疗后,紫杉醇脂质体组患者远期疗效高于培美曲塞组,差异具有统计学意义(P<0.05);两组患者近期疗效、不良反应发生率差异无统计学意义(P>0.05)。结论临床治疗Ⅳ期肺腺癌患者时,采用紫杉醇脂质体联合卡铂治疗具有良好的治疗效果,提高患者的远期生存率,且不会增加不良反应发生率,具有较高的临床应用价值。
Objective To observe the curative effect and survival difference of paclitaxel liposome combined with carboplatin in treatment of stage IV lung adenocarcinoma. Methods 50 patients with stage Ⅳ lung adenocarci-noma from January 2013 to May 2014 were given paclitaxel liposome combined with carboplatin therapy, and another 50 patients with stage Ⅳ lung adenocarcinoma were treated with pemetrexed combined with carboplatin. Their recent curative effect and adverse reaction were observed in the two groups, and they were followed-up for 20 months. Results After treatment, the long-term curative effect was better in the paclitaxel liposome group in the pemetrexed group （ P 〈 0. 05 ）. There was no significant difference in the short-term curative effect and adverse reactions between the two groups （ P 〉 0. 05 ） . Conclusion Paclitaxel liposome combined with carboplatin has good therapeutic effect in treatment of stage Ⅳ lung adenocarcinoma, which can improve the long-term survival rate of patients, and will not increase the incidence of adverse reactions.
出处
《临床肺科杂志》
2017年第7期1212-1214,共3页
Journal of Clinical Pulmonary Medicine
基金
2015年浙江省医药卫生一般研究计划(A类)
(No2015KYA040)
关键词
紫杉醇脂质体
卡铂
Ⅳ期肺腺癌
疗效
paclitaxel liposome
carboplatin
stage IV lung adenocarcinoma
curative effect
